- Home
- NEA vs SRRK Comparison
NEA vs SRRK Comparison
Compare NEA & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEA
- SRRK
- Stock Information
- Founded
- NEA 2002
- SRRK 2012
- Country
- NEA United States
- SRRK United States
- Employees
- NEA N/A
- SRRK N/A
- Industry
- NEA Finance/Investors Services
- SRRK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NEA Finance
- SRRK Health Care
- Exchange
- NEA Nasdaq
- SRRK Nasdaq
- Market Cap
- NEA 3.4B
- SRRK 2.8B
- IPO Year
- NEA N/A
- SRRK 2018
- Fundamental
- Price
- NEA $11.52
- SRRK $26.49
- Analyst Decision
- NEA
- SRRK Strong Buy
- Analyst Count
- NEA 0
- SRRK 7
- Target Price
- NEA N/A
- SRRK $34.00
- AVG Volume (30 Days)
- NEA 803.4K
- SRRK 984.5K
- Earning Date
- NEA 01-01-0001
- SRRK 11-12-2024
- Dividend Yield
- NEA 4.23%
- SRRK N/A
- EPS Growth
- NEA N/A
- SRRK N/A
- EPS
- NEA N/A
- SRRK N/A
- Revenue
- NEA N/A
- SRRK N/A
- Revenue This Year
- NEA N/A
- SRRK N/A
- Revenue Next Year
- NEA N/A
- SRRK N/A
- P/E Ratio
- NEA N/A
- SRRK N/A
- Revenue Growth
- NEA N/A
- SRRK N/A
- 52 Week Low
- NEA $9.20
- SRRK $6.76
- 52 Week High
- NEA $11.37
- SRRK $35.38
- Technical
- Relative Strength Index (RSI)
- NEA 45.46
- SRRK 50.87
- Support Level
- NEA $11.46
- SRRK $25.86
- Resistance Level
- NEA $11.61
- SRRK $28.11
- Average True Range (ATR)
- NEA 0.11
- SRRK 1.68
- MACD
- NEA 0.02
- SRRK -0.92
- Stochastic Oscillator
- NEA 59.21
- SRRK 11.71
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGFβ1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.